中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

34 records (took 0.041 seconds)

    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS
    4.
    发明申请
    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS 失效
    作为蛋白激酶抑制剂的化合物和组合物

    公开(公告)号：US20100048552A1

    公开(公告)日：2010-02-25

    申请号：US12299687

    申请日：2007-05-11

    Applicant: Pingda Ren ,  Baogen Wu ,  Guobao Zhang ,  Yongping Xie ,  Barun Okram ,  Victor Nikulin ,  Xia Wang ,  Ha-Soon Choi

    Inventor： Pingda Ren ,  Baogen Wu ,  Guobao Zhang ,  Yongping Xie ,  Barun Okram ,  Victor Nikulin ,  Xia Wang ,  Ha-Soon Choi

    IPC: A61K31/4375 ,  C07D471/14 ,  A61K31/5377 ,  A61P43/00

    CPC classification number: C07D471/14

    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

    Abstract translation: 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，Bcr-Abl异常活化的疾病或病症 ，Bcr-Abl（T315I），ALK，BLK，BMX，BRK，C-kit，c-RAF，CSK，c-SRC，EGFR，Fes，FGFR3，Flt3，Fms，Fyn，IGF-1R，IR，JAK（ 2），JAK（3），KDR，Lck，NLK，p70S6K，PDGFRα，Ros，SAPK2α，SGK，SIK，Syk，Tie2和TrkB激酶。

    COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS
    5.
    发明申请
    COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS 审中-公开
    FGF受体激酶抑制剂的组合物和方法

    公开(公告)号：US20090312321A1

    公开(公告)日：2009-12-17

    申请号：US12300088

    申请日：2007-04-06

    Applicant: Pingda Ren ,  Guobao Zhang ,  Shuli You ,  Taebo Sim ,  Nathanael S. Gray ,  Yongping Xie ,  Xing Wang ,  Yun He

    Inventor： Pingda Ren ,  Guobao Zhang ,  Shuli You ,  Taebo Sim ,  Nathanael S. Gray ,  Yongping Xie ,  Xing Wang ,  Yun He

    IPC: A61K31/5377 ,  C07D471/04 ,  A61K31/4375 ,  C07D487/04 ,  A61K31/519

    CPC classification number: C07D487/04 ,  C07D471/04

    Abstract: Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as Abl, ALK, AMPK, Aurora, Axl, Bcr-Abl, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDK1, CHK2, CK1, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphB1, FES, FGFR1, FGFR2, FGFR3, Flt1, Flt3, FMS, Fyn, GSK3β, IGF-1R, IKKα, IKKβ, IR, IRAK4, ITK, JAK2, JAK3, JNK1α1, JNK2α, KDR, Lck, LYN, MAPK1, MAPKAP-K2, MEK1, MET, MKK4, MKK6, MST2, NEK2, NLK, p70S6K, PAK2, PDGFR, PDGFRα, PDK1, Pim-2, Plk3, PKA, PKBα, PKCα, PKCtheta, PKD2, c-Raf, RET, ROCK-I, ROCK-II, Ron, Ros, Rsk1, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70.

    Abstract translation: 描述的是化合物，包含这些化合物的药物组合物，以及使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或紊乱的方法，特别是涉及激酶例如Abl，ALK，AMPK，Aurora的异常活性的疾病或病症 ，Ax1，Bcr-Abl，BIK，Bmx，BRK，BTK，c-Kit，CSK，cSrc，CDK1，CHK2，CK1，CK2，CaMKII，CaMKIV，DYRK2，EGFR，EphB1，FES，FGFR1，FGFR2，FGFR3，Flt1 ，Flt3，FMS，Fyn，GSK3beta，IGF-1R，IKKalpha，IKKbeta，IR，IRAK4，ITK，JAK2，JAK3，JNK1alpha1，JNK2alpha，KDR，Lck，LYN，MAPK1，MAPKAP-K2，MEK1，MET，MKK4，MKK6 ，MST2，NEK2，NLK，p70S6K，PAK2，PDGFR，PDGFRalpha，PDK1，Pim-2，Plk3，PKA，PKBalpha，PKCalpha，PKCθ，PKD2，c-Raf，RET，ROCK-1，ROCK-II，Ron， ，Rsk1，SAPK2a，SAPK2b，SAPK3，SAPK4，SGK，SIK，Syk，Tie2，TrkB，WNK3和ZAP-70。

    Compounds and compositions as protein kinase inhibitors
    10.
    发明授权
    Compounds and compositions as protein kinase inhibitors 失效
    化合物和组合物作为蛋白激酶抑制剂

    公开(公告)号：US07868018B2

    公开(公告)日：2011-01-11

    申请号：US11997113

    申请日：2006-08-09

    Applicant: Yongping Xie ,  Guobao Zhang ,  Xing Wang ,  Nathanael S. Gray ,  Yi Liu

    Inventor： Yongping Xie ,  Guobao Zhang ,  Xing Wang ,  Nathanael S. Gray ,  Yi Liu

    IPC: C07D471/04 ,  A61K31/4375 ,  A61P35/00 ,  A61P37/00 ,  A61P25/00 ,  A61K31/519 ,  C07D413/12 ,  A61K31/5355 ,  A61K31/4355 ,  C07D491/147

    CPC classification number: C07D471/14 ,  C07D471/04 ,  C07D491/14

    Abstract: The invention provides compounds of Formula I: wherein R1-R6 are described in the Summary of the Invention; the pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK2α2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFRβ, PKA, PKBα, PKD2, Rsk1, SAPK2α, SAPK2β, SAPK3, SGK, Tie2 and TrkB kinases.

    Abstract translation: 本发明提供式I化合物：其中R 1 -R 6在发明概述中描述; 包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，Bcr-Abl，BMX，BTK，CHK2，b异常活化的疾病或病症 -RAF，c-RAF，CSK，c-SRC，Fes，FGFR3，Flt3，IKKα，IKK＆bgr;JNK2α2，Lck，Met，MKK4，MKK6，MST2，NEK2，p70S6K，PDGFR＆bgr; PKA，PKBα，PKD2，Rsk1 ，SAPK2α，SAPK2＆bgr，SAPK3，SGK，Tie2和TrkB激酶。

Patent Agency Ranking